Cingulate (CING) Competitors $4.00 -0.15 (-3.61%) Closing price 04:00 PM EasternExtended Trading$3.92 -0.08 (-2.00%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. IMUX, STTK, LITS, ALXO, CLNN, VTVT, KLRS, IMMX, IZTC, and ASRTShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Immunic (IMUX), Shattuck Labs (STTK), Lite Strategy (LITS), ALX Oncology (ALXO), Clene (CLNN), vTv Therapeutics (VTVT), Kalaris Therapeutics (KLRS), Immix Biopharma (IMMX), Invizyne Technologies (IZTC), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Its Competitors Immunic Shattuck Labs Lite Strategy ALX Oncology Clene vTv Therapeutics Kalaris Therapeutics Immix Biopharma Invizyne Technologies Assertio Immunic (NASDAQ:IMUX) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Do analysts rate IMUX or CING? Immunic currently has a consensus price target of $9.50, suggesting a potential upside of 1,034.60%. Cingulate has a consensus price target of $27.75, suggesting a potential upside of 593.75%. Given Immunic's higher possible upside, analysts clearly believe Immunic is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Cingulate 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals hold more shares of IMUX or CING? 51.8% of Immunic shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 4.6% of Immunic shares are owned by insiders. Comparatively, 4.0% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer IMUX or CING? In the previous week, Cingulate had 7 more articles in the media than Immunic. MarketBeat recorded 11 mentions for Cingulate and 4 mentions for Immunic. Immunic's average media sentiment score of 0.62 beat Cingulate's score of 0.12 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, IMUX or CING? Immunic has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500. Which has preferable valuation and earnings, IMUX or CING? Cingulate is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$100.51M-$0.94-0.89CingulateN/AN/A-$15.55M-$4.10-0.98 Is IMUX or CING more profitable? Cingulate's return on equity of -232.16% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -461.46% -217.16% Cingulate N/A -232.16%-132.07% SummaryImmunic beats Cingulate on 7 of the 11 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulateMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.65M$3.39B$6.04B$10.49BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-0.9822.9085.1927.32Price / SalesN/A269.18516.16194.55Price / CashN/A46.9537.5761.53Price / Book1.7210.5312.426.81Net Income-$15.55M-$52.58M$3.32B$276.59M7 Day Performance-4.99%1.06%0.80%0.15%1 Month Performance2.30%16.05%10.52%8.17%1 Year Performance-10.11%18.41%76.14%35.50% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.5421 of 5 stars$4.00-3.6%$27.75+593.8%-8.0%$21.65MN/A-0.9820News CoverageAnalyst ForecastHigh Trading VolumeIMUXImmunic2.2225 of 5 stars$0.89-0.4%$9.50+961.9%-41.9%$88.64MN/A-0.9570STTKShattuck Labs3.8811 of 5 stars$1.84flat$3.00+63.0%+19.9%$88.14M$5.72M-1.52100Positive NewsLITSLite StrategyN/A$2.15-13.0%N/AN/A$88.07M$65.30M-0.45100ALXOALX Oncology4.0618 of 5 stars$1.85+12.8%$3.30+78.4%+9.7%$87.82MN/A-0.8440CLNNClene3.082 of 5 stars$8.25-4.1%$32.60+295.2%+49.4%$86.55M$340K-2.19100News CoverageNegative NewsAnalyst ForecastVTVTvTv Therapeutics1.7434 of 5 stars$21.81-0.2%$35.50+62.8%+66.9%$86.10M$1.02M-6.999Analyst ForecastKLRSKalaris Therapeutics1.3571 of 5 stars$4.76+7.0%$3.00-37.0%N/A$83.23MN/A0.00110News CoverageIMMXImmix Biopharma3.3563 of 5 stars$2.50flat$8.00+220.0%+79.7%$82.59MN/A-3.259News CoveragePositive NewsGap UpIZTCInvizyne TechnologiesN/A$12.95-4.1%N/AN/A$80.96MN/A0.0029ASRTAssertio2.8781 of 5 stars$0.84+0.9%$2.38+182.0%-23.0%$80.36M$124.96M-1.8720Analyst Upgrade Related Companies and Tools Related Companies Immunic Competitors Shattuck Labs Competitors Lite Strategy Competitors ALX Oncology Competitors Clene Competitors vTv Therapeutics Competitors Kalaris Therapeutics Competitors Immix Biopharma Competitors Invizyne Technologies Competitors Assertio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
